HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Franco, D. A. Articles by Greenberg, H. S. Search for Related Content PubMed PubMed Citation Articles by Franco, D. A. Articles by Greenberg, H. S. Related Collections All Immunology All Oncology Chemotherapy-tumor Acute disseminated encephalomyelitis

5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency

From the Department of Neurology, University of Michigan Medical Center, Ann Arbor.

Address correspondence and reprint requests to Dr. Harry S. Greenberg, Department of Neurology, University of Michigan Medical Center, Taubman Center 1914/0316, Ann Arbor, MI 48109; e-mail: hsgr{at}umich.edu

Multifocal inflammatory leukoencephalopathy (MIL) is a cerebral demyelinating syndrome that develops after chemotherapy with 5-fluorouracil (5-FU) and levamisole. The authors report a patient who developed MIL after 5-FU administration not in association with levamisole. She was subsequently diagnosed with partial deficiency of dihydropyrimidine dehydrogenase, an enzyme necessary for 5-FU catabolism. The authors suggest that MIL is a direct result of 5-FU chemotherapy and that patients with dihydropyrimidine dehydrogenase deficiency are at increased risk for this and other toxic effects of 5-FU.

This article has been cited by other articles:

				S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]

				D. W. Kim, H.-J. Kim, D.-E. Kim, and J.-K. Roh Doxifluridine-induced neurotoxicity with normal dihydropyrimidine dehydrogenase activity Neurology, June 8, 2004; 62(11): 2136 - 2137. [Full Text] [PDF]

				M. P. Goetz, M. M. Ames, and R. M. Weinshilboum Primer on Medical Genomics Part XII: Pharmacogenomics--General Principles With Cancer as a Model Mayo Clin. Proc., March 1, 2004; 79(3): 376 - 384. [Abstract] [PDF]